Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Novo Nordisk A/S
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07411560CT.gov A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese | — | Recruiting | — | — | — |
NCT07640139CT.gov Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | — | Enrolling By Invitation | — | — | — |
NCT05078255CT.gov The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes | — | Completed | — | — | — |
NCT01880827CT.gov Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gip (this asset) | Novo Nordisk A/S | P1 | C · 39 |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| Sibutramine | Falquetomed | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Mazdutide | China National Center for Cardiovascular Diseases | P4 | BBB |
| Exenatide | Vivani Medical, Inc | P4 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Gip
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 2 Diabetes Mellitus | — | P1 | CCC · 48 |
| Fatty Liver Disease | — | P1/2 | CCC · 48 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gip in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gip-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →